<tt id="6hsgl"><pre id="6hsgl"><pre id="6hsgl"></pre></pre></tt>
          <nav id="6hsgl"><th id="6hsgl"></th></nav>
          国产免费网站看v片元遮挡,一亚洲一区二区中文字幕,波多野结衣一区二区免费视频,天天色综网,久久综合给合久久狠狠狠,男人的天堂av一二三区,午夜福利看片在线观看,亚洲中文字幕在线无码一区二区
          您現在的位置: > Language Tips > Audio & Video > Special Speed News  
           





            Once-daily pill could simplify HIV treatment
          [ 2006-02-06 15:57 ]


          I’m Steve Ember with the VOA Special English Health Report.


          Myers Squibb and Gilead Sciences have combined many H.I.V. drugs into a single pill
          Sometimes the best medicine is more than one kind of medicine. Malaria, tuberculosis and H.I.V./AIDS, for example, are all treated with combinations of drugs.

          But that can mean a lot of pills to take. It would be simpler if drug companies combined all the medicines into a single pill, taken just once a day.

          Now, two companies say they have done that for people just starting treatment for H.I.V., the virus that causes AIDS. The companies are Bristol-Myers Squibb and Gilead Sciences.

          They have developed a single pill that combines three drugs currently on the market. Bristol-Myers Squibb sells one of them under the name Sustiva. Gilead combined the others, Emtriva and Viread, into a single pill in two thousand four.

          Combining drugs involves more than technical issues. It also involves issues of competition if the drugs are made by different companies. The new once-daily pill is the result of what is described as the first joint venture agreement of its kind in the treatment of H.I.V.

          In January the New England Journal of Medicine published a study of the new pill. Researchers compared its effectiveness to that of the widely used combination of Sustiva and Combivir. Combivir contains two drugs, AZT and 3TC. The researchers say that after one year of treatment, the new pill suppressed H.I.V. levels in more patients and with fewer side effects.

          Gilead paid for the study. Professor Joel Gallant at the Johns Hopkins School of Medicine in Baltimore, Maryland, led the research. He is a paid adviser to Gilead and Bristol-Meyers Squibb as well as the maker of Combivir, GlaxoSmithKline.

          GlaxoSmithKline reacted to the findings by saying that a single study is of limited value. It says the effectiveness of Combivir has been shown in each of more than fifty studies.

          The price of the new once-daily pill has not been announced. But Gilead and Bristol-Myers Squibb say they will provide it at reduced cost to developing countries.

          They plan in the next few months to ask the United States Food and Drug Administration to approve the new pill.

          There are limits to who could take it because of the different drugs it contains. For example, pregnant women are told not to take Sustiva because of the risk of birth disorders.

          Experts say more than forty million people around the world are living with H.I.V.

          This VOA Special English Health Report was written by Cynthia Kirk. Read and listen to our reports at voaspecialenglish.com. I’m Steve Ember.

          Vocabulary

           

           

           
           
           




          主站蜘蛛池模板: 亚洲久热无码av中文字幕| 久热爱精品视频线路一| 91精品国产麻豆国产自产| 国产一级av在线播放| 亚洲欧美人成网站在线观看看| 亚洲综合一区国产精品| 国产精品不卡一区二区久久| 国产综合色在线精品| 精品综合一区二区三区四区| 色猫咪av在线网址| 欧洲免费一区二区三区视频| 成人年无码av片在线观看| 无码熟妇人妻AV在线影片最多| 夜爽8888视频在线观看| 精品人妻无码专区中文字幕| 五月婷婷久久草| 99re免费视频| 无码中文字幕人妻在线一区| 日本三级理论久久人妻电影| 中文无码高潮到痉挛在线视频| 久久精品国产亚洲av麻| 人妻有码av中文字幕久久琪| 色综合人人超人人超级国碰 | 国产人妻精品午夜福利免费| 免费无遮挡毛片中文字幕| 国产一区二区在线视频播放| 国产精品久久久久久久专区| 国产在线拍揄自揄视频网试看 | 亚洲av永久无码精品水牛影视 | 黑人巨茎大战俄罗斯美女| 免费网站看V片在线毛| 欧美福利在线| 亚洲精品成人综合色在线| 亚洲 制服 丝袜 无码| 久久精品国产亚洲欧美| 久久人人爽人人爽人人片aV东京热| 麻豆国产成人AV在线播放| 亚洲国产国语自产精品| 亚洲欧美综合精品成人网站| 一区二区亚洲人妻av| 白丝乳交内射一二三区|